Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.04 | N/A | +42.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.04 | N/A | +42.86% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a cautious optimism about the company's direction. They acknowledged the positive EPS surprise but did not elaborate on revenue expectations.
Management expressed satisfaction with the EPS result despite not providing revenue figures.
They highlighted ongoing projects and potential future developments.
Ligand Pharmaceuticals reported a smaller-than-expected loss per share, which led to a positive stock reaction, rising 6.01%. The lack of revenue figures leaves some uncertainty, but the EPS beat suggests better-than-anticipated performance in some areas. Investors may view this as a sign of resilience in challenging market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN ELEC PWR CO
Jul 31, 2009